Focus List


It’s a Done Deal! Just as we had suspected, Vinergy Resources (VNNYF) today announced the signing of a definitive agreement to acquire 100% of MJ Biopharma, a cannabis technology company. We have been speculating for over a week that the halt of trading on the Canadian exchange for symbol VIN.CN was to allow for this completed acquisition, and we were right. The stock has gained as much as 36% since we re-initiated coverage on VNNYF last week in anticipation of this deal closing. But now the real fun begins…

This is a major milestone for VNNYF and its shareholders that gives a true fundamental boost to the company. The investment community has been waiting for closure on this item for some time now dating back months ago when the company first mentioned its plans for the acquisition. Back then Vinergy’s stock skyrocketed on the possibility of the deal closing but soon pulled back as investors perhaps grew tired of waiting for a definitive deal, or maybe they doubted the whole deal altogether.

Well, now today’s news from VNNYF of a signed definitive agreement will put all that uncertainty and impatience to rest while sparking a new level of interest and excitement.

Incentivized Compensation Plan

Perhaps the most exciting piece of this acquisition is the means in which Vinergy is acquiring MJ Biopharma. 4.25M shares of common stock priced at $0.20CAD are to be issued upfront, 2/3 of which will be held in escrow. But MJ Biopharma management and shareholders have the opportunity to earn an additional 5M shares is they bring each of their 4 product segments to commercialization. This is a genius move by VNNYF management that could drastically increase shareholder value down the road.

What is VNNYF Acquiring?

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems;


MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.


The Big Picture is Starting to Come Together

The company said their novel approach for its breath strip technology may become the basis for new products where water or saliva is the catalyst to activate the carrier for delivery and absorption of CBD into the body. Management believes this breakthrough could form the basis of a new technology and has the potential to create an entirely new product category. The technology is called BURST, named for the speed at which it enhances the body’s absorption of various ingredients.

And let’s not forget that VNNYF signed a binding letter of intent to acquire 65% of Biolennia Laboratories. Biolennia Labs is a specialty development laboratory with expertise in microbiology and chemistry. The lab operates out of a secure facility in Toronto alongside Micrylium, which manufactures products registered under license from several agencies. It currently provides testing, R&D, and quality control for Health Canada registered and approved industrial disinfectants and other consumer products on behalf of Micrylium.

Vinergy also reported the development of a disruptive solvent-based extraction system. The project is already underway and the company will be providing updates and more information soon. Positive results from this project could be another strong catalyst for VNNYF. And with the acquisition of MJ Biopharma finally completed, all the pieces appear to be falling perfectly into place.

What was once speculation and hype that ignited nearly a 200% move in Vinergy’s stock months ago when this acquisition was just a “possibility” has just officially become reality. The structure of this deal and the current market conditions could present great opportunity for VNNYF shareholders. So far we have seen VNNYF gain as much as 36% since we re-initiated coverage on the company but with this acquisition finally in the books, this could be just the beginning.

Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 2373
cannabis biotech

VANCOUVER, BRITISH COLUMBIA–( – May 9, 2017) – Vinergy Resources Ltd. (“Vinergy” or the “Company”) (CSE:VIN)(VNNYF) is pleased to announce that it has signed a definitive agreement (the “Agreement“) with 1099955 B.C. LTD. dba MJ BioPharma (“MJ BioPharma“) whereby Vinergy will purchase 100% of MJ BioPharma, a cannabis technology company. Pursuant to the terms of the Agreement, the Company will acquire all of the issued and outstanding securities of MJ BioPharma (the “Transaction“).

About MJ BioPharma

MJ Biopharma is a cannabis technology company with a team of experienced business and medical professionals, biochemists and researchers. The company is currently focused on the following areas of interest:

  • manufacturing breath strips;
  • time release capsules;
  • extract oils;
  • food products and infused juices, teas, coffee and extract drinks;
  • pharmaceutical grade delivery systems.

MJ Biopharma’s expertise lies in its extracts and custom formulations. The company will also aim to inlicense and joint venture on best in class technologies and products for both the medicinal and recreational markets – domestically and internationally.

Definitive Agreement

Pursuant to the terms of the Agreement, the Company will, upon closing of the Transaction, issue to MJ BioPharma shareholders an aggregate of 9,750,000 common shares in the capital of the Company (the “Payment Shares”) at a deemed price of CDN$0.20 per Payment Share. The Payment Shares will be subject to escrow conditions and/or resale restrictions as required by applicable securities laws and the policies of the Canadian Securities Exchange (the “CSE”). A finder’s fee of 400,000 common shares in the capital of the Company, subject to CSE approval, will be payable on this Transaction.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding “Forward-Looking” Information

The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information.

The best Marijuana Stocks / Cannabis Stocks to Watch in 2017 & Beyond.

Earlier this year we covered the market for marijuana stocks post Trump and many of these marijuana stocks have continued to see progress over the time since. Now that we’re finally through the transitional period, it’s time to look ahead at marijuana stocks to watch in 2017 and even beyond. Who would have thought this industry would have come this far, let alone open up the doors to an entirely new and evolving sector.

In fact, according to new research, North American sales are projected to top $20.2 billion by 2021. Marijuana sales in North America grew by an unprecedented 30% in 2016 to $6.7 billion as the legal market expands in the U.S. and Canada, according to a report from Arcview Market Research. So, it’s hard not to find the best marijuana stocks to watch this year and in the years to come.  Several we have watched, mentioned, reported on, and reviewed very recently with favorable market activity in play.

First and foremost, mCig, Inc. (MCIG) is a company we’ve watch grow immensely over the last few months.  Since it was trading around 2 and a half cents in September, MCIG has seen highs of as much as $0.505.  The stock has been upholding a channel roughly between $0.30 and $0.40 for the last few weeks and multiple announcements show, in our opinion, that company’s focus on really building shareholder value including triple digit sales growth, canceling 20 million shares  and converting another 60 million shares into preferred that also carry with it a 2 year lock up.  The company has also announced that it will be reporting on its “record financial growth numbers and cost basis investments; to include, Vapolution, VitaCBD, Omni Health (OTC PINK: OMHE,) Agri-Contractors, and other strategic partnerships.”
The Green Organic Dutchman Holdings Ltd. (TGOD) comes onto this list following the roll-out of our previous coverage on now public company, Emblem Corp (EMMBF). Emblem was one of the most anticipated offerings that has come out of Canada in the last few months.  For TGOD, besides being licensed under the access to cannabis for medical purposes regulations (ACMPR) to cultivate medical marijuana, TGOD has some big names behind it from a financing front including familiar faces from the Emblem & Organigram camps.

In addition to this, the company has 1,000 kg current annual indoor operating capacity as well as a newly acquired property coming in at 75 acres, which adjoins the current facility. The planned IPO of TGOD is in October, more details here.

We looked at OWC Pharmaceutical Research Corp.  (OWCP).  This was trading around $0.95 and recent trading activity has seen this hit as high as $3.23.  The company has most recently been adding to its advisory board.  Both Dr. Sharon Rozenblat and Ms. Miriam Sani, MSc Eng. Dr. Rozenblat will be overseeing the completion of the pre-clinical safety studies on the Company’s treatment for psoriasis, which commenced in November 2016 and Sani is the CEO and owner of “Shefa Amirim” Ltd, which provides regulatory affairs and clinical consultation services for early-stage start-ups in various medical fields. The company itself focuses on two things: 1. medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines and 2. OWCP is developing unique delivery systems for the effective delivery and dosage of medical cannabis.

Rocky Mountain High Brands (RMHB) is another company we’ve watched since the days it was called Totally Hemp Crazy and ever since, we’ve seen this company grab attention of the market.  The company specialized in hemp infused beverages and more recently an alkaline water called Eagle Spirit, which was issued a trademark on Feb 22. Aside from this, the company has been implementing a partnership strategy, enhancing its internal fulfillment operations, as well as making it a known presence at industry conventions.  As of Wednesday 2-22-2017, shares of Rocky Mountain High had hit highs of $0.118.

Advantis Corp. (ADVT) was a company we started watching last summer and since the beginning of the year, we picked back up on it.  There’s enough going on here in our opinion to take notice of including the recent announcements that the company has taken steps to become a fully-reporting public company as well as launched distribution of topical cannabis roll-on and Tinctures to treat pain conditions. This also comes as the company has begun to further expand on its overall product offering so just like we cited at first “way back when” with Totally Hemp Crazy, we think that ADVT could be another company to follow during its infancy.  Since we picked back up on this, we’ve also watched as ADVT climbed from around $0.005 to highs of $0.035 during the last full week of February.

Aurora Cannabis Inc. (TSXV: ACB) (OTCQB: ACBFF) made our list a few months ago and it has kept its spot especially considering the move for Canada’s legalization. The company’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations and operates a 55,200 square foot, expandable, state-of-the-art production facility in Mountain View County, Alberta, Canada. In addition to partnership and collaboration deals with the like of companies like Radient Technologies (RTI.V), this company has also obtained significant financial contributions through its bought deal private placement with a syndicate of underwriters led by Canaccord Genuity Corp. for aggregate gross proceeds to Aurora of $60,007,500.

Other Canadian marijuana stocks to watch include Canopy Growth (WEED.TO), which just announced that it has entered into a memorandum of understanding with Namaste Technologies Inc. “to define the intention of Namaste and Canopy to expand their respective market positions by seeking to form multi-point working arrangements and exploring the development of new delivery devices for the consumption of cannabis.”

Namaste’s database consists of approximately 300,000 customers that generate upwards of 600,000 site visits monthly. Namaste also has 26 e-commerce retail stores in 20 countries. We watch now in the midst of all of the developments as Canopy has grown from a stock trading under $3 to today’s price of more than $12/share.

Future Farm (CSE: FFT) (OTCQB: FFRMF) formerly AGSTF, this company is something we’ve covered from very early on.  This company has been aggressively expanding into the marijuana space.  The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment.  We began following this at $0.137 and this week it has managed to hit highs of $0.50; a solid run of 265% so far and could certainly be something to be watching into 2017.

Similar to Aurora, Aphria, Inc. (APH.V) (APHQF) has entered into an agreement with Clarus Securities to which the Underwriters have agreed to purchase, on a “bought deal” basis, 10,000,000 Common Shares of the Company at a price of C$5.00 per Common Share for aggregate gross proceeds to the Company of C$50,000,000. This is expected to close on or about February 24 of this year. The company also recently received approval to jump from the TSX Venture Exchange to list on the TSX and depending on meeting certain conditions, is expected to be finalized on or before the TSX imposed May 3rd, 2017 deadline. The stock on the US exchange and the Canadian exchange has been on an uptrend since last March.

0 4104

Today’s news while very positive also highlights the brash speculation in the market place. CEO’s usually read most of this fodder and usually have a chuckle at the absurdity of some of this “information” people try and pass as honest speculation. I myself pay attention, because once you poke through the fragile veneer of what is being said lies the root of closing down that round of speculation.

Today we announced that FBEC is retiring a note and I’m sure most people that have common sense and aren’t irrational will see that as positive news; which it is. The speculation on this subject matter has been for the last two months that the stock was going to under intense pressure once this note matured. The note has been referenced by the 11/15 date by “Speculators/Alarmists” yelling “fire” in an empty room for some time now. I wanted to take this moment to offer them an apology for making their posts on this topic null & void. I also want to point out the irony that they are in fact “crying Wolf,” which I find amusing on a few different levels.

Moments of levity are important when you’re CEO of a public company, but what’s more important is that you say what you mean, and mean what you say. Roughly 70 days ago the speculators were ringing their bells and regurgitating the same info over and over because they “care” and are completely “altruistic” when it comes to investors. Unfortunately they have been proven wrong at every turn with their assumptions and continue to look more like a homeless guy in Time Square holding up a sign that reads “spare some change, the end is near.”

FBEC is delivering, as one speculator writes “charts don’t lie,” and we will continue to deliver in the coming months and deliver on what we said we would. I promise to keep bringing different revenue verticals to FBEC to strengthen its balance sheet and portfolio of holdings. Feel free on speculating as to what might come next…


Jason Spatafora


FBEC WorldWide Inc.

Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use.

After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year.  Companies like Oxis International (OXIS), Pazoo, Inc. (PZOO), and Totally Hemp Crazy Inc (THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.

Oxis International,  (OXIS) saw highs of $0.07 less than 45 days ago.  Earlier this week, Oxis announced its wholly owned subsidiary, Oxis Biotech, had brought on Cassian Yee, M.D.  Yee is a Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center as well as Professor, Department of Immunology, Division of Cancer Medicine, and Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research at the University of Texas MD Anderson Cancer Center.

“We are very excited to have the opportunity to work with Cassian again, and we look forward to his helping us build Oxis into a leading cancer immunotherapy company,” said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.

Thursday afternoon Oxis shares battled back from intra-day lows of $0.03 to close the Thursday session at $0.0322, up 7% from those lows. Since the opening day of 2015, Oxis has moved up by as much as 100% (Jan 2 $0.035 open to March 31 High of $0.07)

Pazoo Inc. (PZOO) has also seen a jump in price since the beginning of the year.  After opening on January 2 at $0.0194, PZOO saw it’s record high on April 27 ($0.0204).  Though the stock had fallen briefly, in February, the recent rally in the market may have been spawned by new company developments.  This month Pazoo announced that members of its staff will be attending several investment and marijuana conferences over the month of May. Pazoo is also announced it will have a booth at the 4th Annual Marijuana Business Conference and Expo, America’s largest national cannabis trade show, being held in Chicago, May 19-21.

During the past week Pazoo has maintained a price channel between $0.01-$0.0124.

Totally Hemp Crazy Inc. (THCZ) may have seen one of the largest moves in price of many cannabis stocks.  After opening the year at $0.012, Totally Hemp Crazy saw highs of $0.32 at the beginning of April and tested these highs once more just before the beginning of May. Totally Hemp has gained notoriety for its novel hemp infused beverages under the Rocky Mountain High brand. This week it was announced that the company’s CEO Jerry Grisaffi will be interviewed on WWNN – 1470AM, a Beasley Broadcasting Network station. The broadcast can be heard live on south Florida radio WWNN -1470AM and streamed live on video TV at Mr Grisaffi will be interviewed, Friday, May 15, 2015 at noon EDT. Grisaffi recently stated, “The Rocky Mountain High retail product launch is underway and based on initial sales and consumer reactions, we are convinced we have something special. In just a few short months, production has exceeded 1,000,000 units and we have another larger production run scheduled for June. We are confident our rapid growth will lead to a nationwide hemp infused drink sensation. Based on the current feedback from other parties, we are not alone in that belief.”

About is the leading web destination for all things cannabis. Investors can find marijuana related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

MAPH Enterprises LLC, which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC,  which owns, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.


Contact Information:


Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements